WASHINGTON (Reuters) - U.S. regulators alerted the public on Friday to a study showing a higher death rate among heart disease patients a year after taking an Abbott Laboratories Inc. antibiotic, as part of an effort to release early information about potential safety concerns. Officials have not reached a final conclusion about the information, the notice on the Food and Drug Administration Web site said.
